We have located links that may give you full text access.
Journal Article
Review
B large-cell lymphoma in children and adolescents.
Cancer Treatment Reviews 2003 April
The prognosis of advanced B-large cell lymphoma (B-LCL) in children and adolescents has improved dramatically over the past 25 years (30-40% to 80-90% 5-year event-free survival (EFS)). Using strategies of treatment allocation based upon risk of disease recurrence, the total duration of therapy has been successfully reduced for many patients, and the prior requirement for radiotherapy largely eliminated. Instead of 18-30 months of combined chemotherapy and radiotherapy, current therapy has been decreased to between 6 weeks and 6 months of intensive chemotherapy. Multiagent chemotherapeutic approaches have been optimized with the use of moderate to high-dose methotrexate and further intensification with cytarabine and etoposide. The prognosis for children and adolescents who progress or relapse on current therapy for B-LCL, however, has decreased over the past 25 years with approximately 80% or 90% surviving at the present time. B-LCL in children and adolescents uniformly expresses CD20 and CD22 surface antigens. New treatment strategies employing targeted monoclonal antibody therapy combined with chemotherapy and targeted conjugated monoclonal antibody therapy conjugated with radioactive compounds and toxins are currently being investigated. Future studies utilizing immunophenotyping, cytogenetics, molecular genetics, and gene expression profiles (microarray) are required to better define the biological heterogeneity and differential clinical outcomes among children and adolescents with B-LCL.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app